Silence Therapeutics plc
SLNCF
$1.69
$0.0855.31%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 4.12% | -375.94% | 129.41% | -77.93% | -754.46% |
| Total Depreciation and Amortization | 7.25% | -7.88% | 0.07% | -0.20% | -1.32% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 77.50% | 149.24% | -229.27% | 169.20% | -2.31% |
| Change in Net Operating Assets | -142.91% | 139.21% | -4,287.81% | -94.16% | 205.91% |
| Cash from Operations | -76.98% | 55.44% | -7.99% | -372.89% | 40.84% |
| Capital Expenditure | -1,100.00% | 93.92% | -3.13% | 24.94% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 96.59% | -171.13% | 266.51% | -89,308.10% | 100.08% |
| Cash from Investing | 96.48% | -171.21% | 266.05% | -87,181.63% | 99.91% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 473.06% | -- | -- |
| Issuance of Common Stock | -92.86% | -- | -- | 431.35% | -99.10% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 2,769.88% | -- | -- |
| Cash from Financing | -92.86% | -99.00% | -82.01% | 550.98% | -99.10% |
| Foreign Exchange rate Adjustments | -14.66% | -96.45% | 200.34% | -46,375.71% | 60.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 58.99% | -232.43% | 168.91% | -1,347.46% | -105.78% |